Merck, Pfizer Decorate Consumer Health 'For Sale' Signs With Strong Results
Merck KGAA reports 11% growth in sales of its OTC lines over a year ago, but, like Pfizer, looks to sharpen its long-term focus on the Rx business.
Merck KGAA reports 11% growth in sales of its OTC lines over a year ago, but, like Pfizer, looks to sharpen its long-term focus on the Rx business.